Astellas

Summary

Astellas Pharma Inc was formed on 1st April 2005 from the merger of Yamanouchi and Fujisawa. The aim of Astellas is to secure a top share in the Japanese pharmaceutical market; the combined company now has 5,000 medical representatives, the largest among domestic pharmaceutical companies, and it aims to develop an even stronger sales and marketing infrastructure. The company also expects to be able to provide broad coverage for both primary care physicians and speciality markets in the US by leveraging the existing infrastructures to accelerate expansion of the US business.

The merger of Yamanouchi and Fujisawa brought together two very complementary R&D pipelines, putting Astellas in a very strong position in the domestic Japanese market. The combined company has concentrated its core business on pharmaceuticals and related products, split into six key franchise fields and priority research areas; urology, inflammation, diabetes, infectious diseases, gastrointestinal disease and the central nervous system.

Astellas has a number of licensed-in products, which have been proven overseas by partner companies. These products, such as Micardis, Luvox, Seroquel, Eligard and Myslee, are regarded as Synergy Products' by Astellas and should provide the foundation for future growth. Astellas is throwing its weight behind these products with support from all of its medical sales representatives and Area Marketing Supporters. For other key products Astellas has divided up its sales force into two: GA

Contents

• Executive Summary
  • A Detailed and Comprehensive Overview of Current Financial Position, Company Strategy, Product and Pipeline Analysis.
• Therapeutic Area Focus
  • Key Product Analysis and Forecasting
  • Cardiovascular
    • Adenocard (Adenosine)
    • Adenoscan (Adenosine)
    • Cibenol (Cibenzoline)
    • Dorner (Beraprost)
    • Frandol (Isosorbide Dinitrate)
    • Hypoca/Cyress (Barnidipine)
    • Lexiscan (Regadenoson)
    • Lipitor (Atorvastatin)
    • Micardis (Telmisartan)
    • Milrila (Milrinone)
    • Nivadil (Nilvadipine)
    • Perdipine (Nicardipine)
    • Solinase (Pamiteplase)
    • Vaprisol (Conivaptan)
  • Urology
    • Harnal/Omnic/Flomax (Tamsulosin)
    • Vesicare (Solifenacin)
  • Inflammation & Immunology
    • Atock/Foradil (Formoterol Fumarate)
    • Celecox (Celecoxib)
    • Intal (Sodium Cromoglycate)
    • Prograf (Tacrolimus)
  • Gastrointestinal
    • Colonel (Hsr 237) (Polycarbophil Calcium)
    • Ganaton (Itopride)
    • Gaster/Pepcid (Famotidine)
    • Nasea (Ramosetron)
  • Infectious Disease
    • Aimmugen (Hepatitis A Vaccine)
    • Ambisome (Liposomal Amphotericin)
    • Cefamezin (Cefazolin)
    • Cefspan (Cefixime)
    • Cefzon/Omnicef (Cefdinir)
    • Funguard/Mycamine (Micafungin)
    • Geninax (Garenoxacin)
    • Infergen/Advaferon (Interferon Alfacon-1, Ym643)
    • Targocid (Teicoplanin)
  • Central Nervous System
    • Dogmatyl (Sulpiride)
    • Luvox (Fluvoxamine)
    • Myslee (Zolpidem)
    • Seroquel (Quetiapine)
  • Dermatology
    • Amevive (Alefacept)
    • Protopic (Tacrolimus)
  • Metabolic
    • Starsis (Nateglinide)
  • Bone Disorders
    • Inductos (Ym484; Rhbmp-2, Dibotermin Alpha)
  • Oncology
    • Eligard (Leuprolide)
    • Smancs (Zinostatin Stimalamer)
• Operational Data
  • A Wealth of Background and Detail
  • A Full 5-Year Financial Performance Assessment
  • Key Corporate Events
  • Key Agreements
  • Infrastructure
  • Subsidiaries and Joint Ventures